Physician profile
Heidi Capodarco
NPI 1669992004
$1,376.68
in general payments reported to CMS, 2019-2025
14 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.14 · 2023: $389 · 2024: $500 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.54 |
| Education | $179.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $425.39 | 2023-2025 | Lynparza, Keytruda, Welireg |
| Taiho Oncology, INC. | $315.28 | 2023-2025 | |
| Gilead Sciences, INC. | $205.38 | 2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $117.75 | 2025 | Datroway |
| Pfizer INC. | $71.00 | 2023-2024 | |
| Myriad Women'S Health, INC. | $52.96 | 2023 | Myrisk |
| Beigene USA, INC. | $27.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.18 | 2023 | |
| Amgen INC. | $25.70 | 2023 | Lumakras |
| Daiichi Sankyo INC. | $23.85 | 2022 | |
| Celgene Corporation | $23.71 | 2023 | Reblozyl |
| Astellas Pharma US INC | $22.58 | 2023 | Xospata |
| Adc Therapeutics America, INC. | $20.12 | 2023 | |
| Bio Products Laboratory USA, INC. | $18.49 | 2023 | Gammaplex, Coagadex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Capodarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.